Shionogi & Co., Ltd. announced that a manufacturing and sales marketing approval application has been submitted in Japan for an additional lotion formulation of KorecTive®, a treatment for atopic dermatitis. This submission aims to expand the therapeutic options for patients by offering a new dosage form, potentially increasing market penetration and patient convenience.
The submission of a new lotion formulation for KorecTive® in Japan is a strategic move to enhance its market position in the atopic dermatitis segment. This expansion of dosage forms can improve patient adherence and broaden the drug's applicability, potentially leading to increased sales and market share against competitors offering various formulations.
Shionogi applied for approval of KorecTive® lotion in Japan.
This is an additional formulation for atopic dermatitis treatment.
The submission aims to expand patient options and convenience.
This regulatory submission is specific to Japan, highlighting Shionogi's efforts to adapt and expand its product offerings within the East Asian market to meet local patient needs.
This is an additional formulation for atopic dermatitis treatment.
The submission aims to expand patient options and convenience.
Sign in to save notes on signals.
Sign In